General Thoracic and Cardiovascular Surgery · Nov 18, 2026
Long-term outcomes and benchmarks of redo surgical aortic valve replacement in Japanese patients: insights from a multicenter registry
By Handa K, Maeda K, Yanagino Y et al.
Objective Long-term outcomes following redo surgical aortic valve replacement (SAVR) in Asian patients, who typically have smaller body size than Western populations, remain poorly defined. Contemporary benchmarks are needed as transcatheter aortic valve-in-surgical aortic valve procedures expand. Methods We analyzed 122 patients who underwent redo SAVR for prosthetic valve failure at 8 centers between 2015 and 2023. The primary endpoint was all-cause mortality. Secondary endpoints were cardiac mortality and major adverse cardiovascular and cerebrovascular events (MACCE). Results Median age was 75 years, 50% were male, median body surface area was 1.5 m², and median Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) was 7.4%. All-cause mortality at 1, 3, and 5 years was 9.9, 15.8, and 26.2%, respectively. Five-year all-cause mortality was higher in patients with STS-PROM ≥ 8% than in those with STS-PROM < 8% (45.2% vs. 15.5%; P < 0.001), but was not associated with age ≥ 75 years. Cardiac mortality at 1, 3, and 5 years was 6.8, 10.9, and 12.4%, respectively. Five-year cardiac mortality was higher in patients with STS-PROM ≥ 8% (20.9% vs. 7.7%; P = 0.047), but was not associated with age ≥ 75 years. MACCE at 1, 3, and 5 years was 15.8, 19.7, and 31.9%, respectively, and was associated with both STS-PROM ≥ 8% (44.2% vs. 25.1%; P = 0.008) and age ≥ 75 years (42.4% vs. 22.9%; P = 0.011). STS-PROM ≥ 8% and hemodialysis independently predicted mortality. Conclusions Redo SAVR was performed primarily in older, small-bodied, and relatively high-risk Asian patients. Careful patient selection may be warranted, particularly in patients with high STS-PROM or those undergoing hemodialysis.
doi.org/10.1007/s11748-026-02435-zPubMed 43050045Interventions